Triazavirin is an antiviral agent.1 In vivo, triazavirin (1 mg/kg) inhibits lung viral accumulation in a mouse model of H5N1 influenza A infection. Triazavirin (20 mg/kg) inhibits platelet aggregation in a rat model of LPS-induced hypercytokinemia.2 Formulations containing triazavirin have been used in the treatment of influenza.
1.Loginova, S.I., Borisevich, S.V., Maksimov, V.A., et al.Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)Antibiot. Khimioter.56(1-2)10-12(2011) 2.Spasov, A.A., Kucheryavenko, A.F., Sirotenko, V.S., et al.Antiplatelet activity of riamilovir under conditions of lipopolysaccharide intoxicationBull. Exp. Biol. Med.173(1)41-45(2022)